Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Loading story…
5 views
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
More in Business
Same desk, different stories
BusinessIf Only the Profanity Meant an End Was in Sight
Markets have a lot to weigh up, but optimism took a bruising over Easter weekend. Markets have a lot to weigh up, but optimism took a bruising over Easter weekend.
BusinessEU warns capitals against turning energy crunch into fiscal crisis
Excessive spending to cushion soaring prices would have ‘serious fiscal implications’, says economy commissioner
BusinessWhy this oil shock is different
Governments and central banks are out of policy ammunition to contain the economic fallout
BusinessUkraine’s drones dent Russia’s war-fuelled oil windfall
Disrupted exports are adding pressure to markets already reeling from the war with Iran
BusinessPrivate equity buyouts slump as AI fears and war dent dealmaking
Groups agreed acquisitions worth $172bn in three months to March, a 36 per cent fall from previous quarter
BusinessMaga stands by Trump on Iran — for now
On the streets of small-town Georgia, the president’s base is backing the war as swing voters waver